Patents by Inventor Jamie M. Schiffer

Jamie M. Schiffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240228484
    Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.
    Type: Application
    Filed: January 10, 2024
    Publication date: July 11, 2024
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
  • Patent number: 11891387
    Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: February 6, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
  • Publication number: 20220372030
    Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.
    Type: Application
    Filed: March 25, 2021
    Publication date: November 24, 2022
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne